Subcutaneous Wound Infiltration of Ketamine or Bupivacaine Pain Perception After Cesarean Section
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Aim: To assess the analgesic efficacy of subcutaneous infiltration of ketamine, either alone
or as an adjuvant to bupivacaine, following CS and to compare their effects on postoperative
pain scores and opioid consumption.
Methods: Included patients were allocated to four treatment groups using computer-generated
randomization number chart as follows; Group 1 (Ketamine, n=30) received subcutaneous
infiltration of ketamine, Group 2 (Bupivacaine, n=30) received subcutaneous infiltration of
bupivacaine 0.5%, Group 3 (Ketamine+Bupivacaine, n=30) received subcutaneous infiltration of
ketamine+bupivacaine 0.5% and Group 4 (Placebo, n=30) received subcutaneous infiltration of
placebo (0.9% saline solution). Patients, anesthetist, surgeon, and other medical and nursing
staff were blinded to the contents of the medications. VAS scores at resting and on coughing
and analgesic consumptions were compared.